Specializing in the management of intellectual assets in the life sciences, Dr. Denis worked with academic institutions and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses. Dr. Denis is active in numerous professional organizations and speaks frequently about early stage technology evaluation, formation of start-up companies, conflict of interest and other issues of academic technology transfer.
Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in Human Genetics from University of Texas Medical Branch at Galveston and an undergraduate degree in genetics from Cornell University.
Dr. Gaulton received his Ph.D. in biochemistry and molecular biology from the University of California, Santa Barbara. He conducted postgraduate research in immunology at the School of Public Health and School of Medicine at Harvard University. Dr. Gaulton has published over 100 manuscripts and texts, is an editor and/or reviewer for nine scholarly journals and has been chair of four NIH study sections. As a teacher and researcher, Dr. Gaulton has received numerous awards including the Dean's Award for Basic Science Teaching, the Berwick Memorial Teaching Award, the Lindback Award, the Harry Weaver Neuroscience Scholar Award from the National Multiple Sclerosis Society, and the Leukemia Society Scholar Award.
Mr. Hatfield spent nearly twenty years with Bristol-Myers Squibb Company, and served in various management roles including as Senior Vice President of Bristol-Myers's virology and immunology division, President and General Manager of BMS-Canada, Vice President of US Managed Health care, and a variety of marketing and sales management positions. At BMS, he was directly associated with several product successes, including Pravachol®, Plavix®, Avapro®, Abilify®, Reyataz®, and Atripla®.
Over his career Mr. Hatfield has served on numerous boards including Miragen Therapeutics, aTyr Pharma, InVivo Therapeutics Holding Corp, the Biotechnology Industry Group (BIO), and Ambit Biosciences Corporation. He served as an Adjunct Professor at Purdue University and is on faculty at Drexel University’s LeBow College of Business.
Mr. Hatfield received his Bachelors of Science in Pharmacy from Purdue University's School of Pharmacy and a Master of Business Administration degree from the Wharton School at the University of Pennsylvania.
Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation (JJDC) and Vice President, Corporate Development of Johnson & Johnson since 2004. While at JJDC, Holveck was accountable for equity investments made on behalf of the enterprise and tasked with increasing strategic effectiveness of the company’s key investments. During his tenure, Holveck’s work helped chart a global approach to long term growth initiatives, and build a management and investment team with competencies aligned with the new JJDC vision. Mr. Holveck joined J&J as a company Group Chairman in 1999 following the acquisition of Centocor, Inc., by J&J. Holveck was Chief Executive Officer of Centocor, Inc. at the time of the acquisition and was instrumental in the smooth transition of Centocor into the J&J corporate culture.
Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. While in this role, Holveck solidified confidence of key shareholders in the organization, restructured the company’s financial underpinnings to increase profitability, and established partnering relationships with leading pharmaceutical companies for the development of various medicines.
Mr. Holveck launched his career in the pharmaceutical industry after ending his service with the U.S. Navy after an honorable discharge. Prior to his military service, Holveck received his B.A. in Education from West Chester University.
In addition to his administrative leadership positions, Dr. Kaufman maintained an active research program investigating the genetics of blood diseases and cancer over his career. While at Duke, he had a medical practice in internal medicine and hematology/oncology, and was director of the hemoglobin and protein clinical laboratory as well as developer of the molecular diagnostic laboratory.
Dr. Kaufman has been a pace-setter for the growing life sciences industry in the greater Philadelphia region, having served on the board of directors for the Greater Philadelphia Chamber of Commerce; Select Greater Philadelphia’s CEO Council for Growth; the Greater Philadelphia Life Sciences Congress; the University City Science Center; BioAdvance – Biotechnology Greenhouse Corporation of Southeastern Pennsylvania; The University of the Sciences; and Osage Ventures II before joining Pappas-Capital.
With long-standing interests in both basic and applied cancer research, Dr. Kaufman has held leadership positions in national academic organizations in internal medicine and on committees within the National Institutes of Health, the National Academy of Sciences, and the American Association of Medical Colleges. A fellow of the American College of Physicians, he has received honors and awards for his work from the March of Dimes, the Leukemia and Lymphoma Society of America, the Arthritis Foundation, and others. The American Cancer Society awarded Dr. Kaufman with the 2008 Southeast Region Cancer Control Award, in recognition of his exemplary individual achievements in the field of cancer control. Dr. Kaufman was also named one of the first Searle Scholars, a prestigious program that supports top-flight academic research in biomedicine and chemistry.
He earned a Bachelor’s degree in Zoology and Biochemistry from the Ohio State University, and earned his medical degree from the Ohio State University College of Medicine.
Dr. U'Prichard began his career in academia as tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School after his postdoctoral fellowship at The Johns Hopkins University. Following his academic career, Dr. U’Prichard was instrumental in the launch of Nova Pharmaceuticals, Baltimore MD in 1983.
Dr. U'Prichard later served as Chairman of Research and Development at SmithKline Beecham, managing 8,000 R&D staff and a portfolio of 200 projects. Prior to SmithKline Beecham, he worked for ICI/Zeneca as Executive Vice President and International Research Director.
As Venture Partner for Red Abbey Venture Partners (Baltimore), Apax Partners Ltd. (London), and Care Capital LLC (Princeton), Dr. U’Prichard provided expert guidance of early stage life science companies.
Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, The Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow. He is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards.